Core-binding factor acute myeloid leukemia in first relapse: a retrospective study from the French AML Intergroup.
暂无分享,去创建一个
H. Dombret | J. Tamburini | T. Cluzeau | X. Thomas | C. Récher | N. Ifrah | P. Rousselot | N. Boissel | C. Berthon | T. Braun | T. Prebet | S. Bertoli | A. Perrot | C. Pautas | J. Cahn | B. Lioure | M. Hospital | Edouard Randriamalala | E. Tavernier | M. Gourin | J. Konopacki
[1] K. Döhner,et al. Core-binding factor acute myeloid leukemia: can we improve on HiDAC consolidation? , 2013, Hematology. American Society of Hematology. Education Program.
[2] R. Hills,et al. Curability of patients with acute myeloid leukemia who did not undergo transplantation in first remission. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[3] J. Cayuela,et al. Prospective evaluation of gene mutations and minimal residual disease in patients with core binding factor acute myeloid leukemia. , 2013, Blood.
[4] H. Dombret,et al. Evaluation of allogeneic hematopoietic SCT in younger adults with adverse karyotype AML , 2012, Bone Marrow Transplantation.
[5] G. Wilding,et al. Cytoreduction with gemtuzumab ozogamicin and cytarabine prior to allogeneic stem cell transplant for relapsed/refractory acute myeloid leukemia , 2012, Leukemia & lymphoma.
[6] H. Dombret,et al. Effect of gemtuzumab ozogamicin on survival of adult patients with de-novo acute myeloid leukaemia (ALFA-0701): a randomised, open-label, phase 3 study , 2012, The Lancet.
[7] P. Chevallier,et al. Early matched sibling hematopoietic cell transplantation for adult AML in first remission using an age-adapted strategy: long-term results of a prospective GOELAMS study. , 2012, Blood.
[8] J. Bourhis,et al. Comparison of high-dose cytarabine and timed-sequential chemotherapy as consolidation for younger adults with AML in first remission: the ALFA-9802 study. , 2011, Blood.
[9] R. Hills,et al. Identification of patients with acute myeloblastic leukemia who benefit from the addition of gemtuzumab ozogamicin: results of the MRC AML15 trial. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[10] J. Bourhis,et al. Randomized study of intensified anthracycline doses for induction and recombinant interleukin-2 for maintenance in patients with acute myeloid leukemia age 50 to 70 years: results of the ALFA-9801 study. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[11] Bob Löwenberg,et al. Review Articles (434 articles) , 2008 .
[12] H. Dombret,et al. Core binding factor acute myeloid leukemia (CBF-AML): is high-dose Ara-C (HDAC) consolidation as effective as you think? , 2009, Current opinion in hematology.
[13] A. Kiani,et al. Gemtuzumab Ozogamicin as Part of Reduced-Intensity Conditioning for Allogeneic Hematopoietic Cell Transplantation in Patients with Relapsed Acute Myeloid Leukemia , 2008, Clinical Cancer Research.
[14] M. Labopin,et al. Identical outcome after autologous or allogeneic genoidentical hematopoietic stem-cell transplantation in first remission of acute myelocytic leukemia carrying inversion 16 or t(8;21): a retrospective study from the European Cooperative Group for Blood and Marrow Transplantation. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[15] H. Dombret,et al. Incidence and prognostic impact of c-Kit, FLT3, and Ras gene mutations in core binding factor acute myeloid leukemia (CBF-AML) , 2006, Leukemia.
[16] C. Bloomfield,et al. Prognostic factors and outcome of core binding factor acute myeloid leukemia patients with t(8;21) differ from those of patients with inv(16): a Cancer and Leukemia Group B study. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[17] H. Dombret,et al. Allogeneic stem cell transplantation in second rather than first complete remission in selected patients with good-risk acute myeloid leukemia , 2005, Bone Marrow Transplantation.
[18] Bob Löwenberg,et al. Prognostic index for adult patients with acute myeloid leukemia in first relapse. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[19] K. Döhner,et al. Individual patient data-based meta-analysis of patients aged 16 to 60 years with core binding factor acute myeloid leukemia: a survey of the German Acute Myeloid Leukemia Intergroup. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[20] K. Shigesada,et al. Mechanism of leukemogenesis by the inv(16) chimeric gene CBFB/PEBP2B-MHY11 , 2004, Oncogene.
[21] L. Peterson,et al. The 8;21 translocation in leukemogenesis , 2004, Oncogene.
[22] C. Bloomfield,et al. Repetitive cycles of high-dose cytarabine benefit patients with acute myeloid leukemia and inv(16)(p13q22) or t(16;16)(p13;q22): results from CALGB 8461. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[23] H. Dombret,et al. Prognosis of inv(16)/t(16;16) acute myeloid leukemia (AML): a survey of 110 cases from the French AML Intergroup. , 2003, Blood.
[24] H. Dombret,et al. A white blood cell index as the main prognostic factor in t ( 8 ; 21 ) acute myeloid leukemia ( AML ) : a survey of 161 cases from the French AML Intergroup , 2002 .
[25] C. Bloomfield,et al. Patients with t(8;21)(q22;q22) and acute myeloid leukemia have superior failure-free and overall survival when repetitive cycles of high-dose cytarabine are administered. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[26] K Wheatley,et al. The importance of diagnostic cytogenetics on outcome in AML: analysis of 1,612 patients entered into the MRC AML 10 trial. The Medical Research Council Adult and Children's Leukaemia Working Parties. , 1998, Blood.
[27] C. Bloomfield,et al. Frequency of prolonged remission duration after high-dose cytarabine intensification in acute myeloid leukemia varies by cytogenetic subtype. , 1998, Cancer research.
[28] P. Grambsch,et al. Proportional hazards tests and diagnostics based on weighted residuals , 1994 .
[29] R Simon,et al. A non-parametric graphical representation of the relationship between survival and the occurrence of an event: application to responder versus non-responder bias. , 1984, Statistics in medicine.
[30] R. Prentice,et al. Commentary on Andersen and Gill's "Cox's Regression Model for Counting Processes: A Large Sample Study" , 1982 .
[31] Nathan Mantel,et al. Evaluation of Response-Time Data Involving Transient States: An Illustration Using Heart-Transplant Data , 1974 .